L3VLUP
ProSign in

ADAPY · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ADAPYARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ADAPY
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterADAPYARGX
Q3 20203 holders, $140m8 holders, $3.6bn
Q4 20203 holders, $108m7 holders, $4.1bn
Q1 20213 holders, $114m8 holders, $4.1bn
Q2 20213 holders, $93m9 holders, $4.6bn
Q3 20212 holders, $108m8 holders, $4.5bn
Q4 20211 holders, $52m9 holders, $5.3bn
Q1 20221 holders, $32m8 holders, $5.3bn
Q2 20221 holders, $26m13 holders, $6.5bn
Q3 20221 holders, $16m14 holders, $5.3bn
Q4 20222 holders, $25m13 holders, $5.5bn
Q1 20231 holders, $19m13 holders, $5.9bn
Q2 20231 holders, $16m18 holders, $6.6bn
Q3 20231 holders, $13m21 holders, $8.7bn
Q4 20231 holders, $13m17 holders, $6.3bn
Q1 20241 holders, $25m13 holders, $6.8bn
Q2 20241 holders, $15m14 holders, $7.9bn
Q3 20241 holders, $16m13 holders, $10.7bn
Q4 20241 holders, $6.4m14 holders, $12.3bn
Q1 2025none listed holders, n.a.17 holders, $11.8bn
Q2 2025none listed holders, n.a.18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 2025none listed holders, n.a.16 holders, $14.8bn
Q1 2026none listed holders, n.a.11 holders, $12.3bn
Q2 2026none listed holders, n.a.14 holders, $15.0bn
ADAPY

Adaptimmune Therapeutics ADR

Holders
1
Reported value
$16m
Buyers
1
Sellers
0

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
13
Reported value
$10.7bn
Buyers
7
Sellers
7

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 14 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ADAPY (1)

Baillie Gifford & Co

Only ARGX (13)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →